GlassScriptPhysician profile
Deborah Townsley
NPI 1881079614
$3,997.91
in general payments reported to CMS, 2019-2025
30 companies · $975 in 2025
The $975 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $775 · 2022: $737 · 2023: $729 · 2024: $782 · 2025: $975.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,486.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,486.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,187.51 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $397.45 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $351.45 | 2021-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $281.67 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $257.68 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $201.94 | 2021-2025 | Trelegy Ellipta, Shingrix |
| Abbvie INC. | $200.44 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $199.12 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.15 | 2021-2022 | |
| Amgen INC. | $109.82 | 2021-2025 | Otezla, Repatha, Enbrel |
| Bayer Healthcare Pharmaceuticals INC. | $89.49 | 2021-2025 | |
| Amarin Pharma, INC. | $81.23 | 2021-2022 | |
| Exact Sciences Corporation | $79.56 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $61.25 | 2024-2025 | Capvaxive, Gardasil 9 |
| Averitas Pharma INC. | $60.23 | 2023 | Qutenza |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $40.01 | 2024 | Veozah |
| Evoke Pharma, INC. | $30.61 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $29.86 | 2022 | |
| Medtronic, INC. | $26.94 | 2024 | Closurefast |
| Janssen Pharmaceuticals, INC | $26.26 | 2021 | |
| Si-Bone, INC. | $22.38 | 2024 | |
| Daiichi Sankyo INC. | $20.00 | 2021 | |
| Esperion Therapeutics, INC. | $19.14 | 2025 | Nexletol |
| Paratek Pharmaceuticals, INC. | $18.36 | 2023 | Nuzyra |
| Xeris Pharmaceuticals, INC. | $17.76 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $15.64 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.38 | 2025 | Caplyta |
| Redhill Biopharma INC. | $14.23 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $13.83 | 2022 | |
| Almatica Pharma LLC | $13.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Townsley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.